Medikamentöse Langzeitbehandlung

Die pharmakologische Langzeittherapie schizophrener Patienten verfolgt primär die folgenden Ziele: Schnelles Erreichen der Remissionsphase, bestmögliche Behandlung von negativen und kognitiven Symptomen, Früherkennung und Behandlung von postakuter psychischer Komorbidität sowie das Erreichen eines möglichst guten sozialen Funktionsniveaus so früh wie möglich. Zum Erreichen dieser Ziele sollte die Pharmakotherapie möglichst wirksam, nebenwirkungsarm und gut akzeptiert sein. Mit mittlerweile 8 verschiedenen Atypika, die derzeit erhältlich sind, ist es bei den meisten Patienten möglich, eine wirksame Rückfallprophylaxe ohne relevante Nebenwirkungen durchzuführen. Die Patientenperspektive sollte systematisch erhoben werden, sie ist für die längerfristige Bereitschaft der Patienten, ihre Medikamente regelmäßig einzunehmen, von größter Bedeutung.

The objectives of long-term pharmacological treatment of schizophrenic patients are mainly: swift achievement of the remission phase, best possible treatment of negative and cognitive symptoms, early diagnosis and treatment of postacute mental comorbidity and the achievement of the best possible level of social functioning as early as possible. To reach these goals, pharmacotherapy should have a high level of efficiency and acceptance and a low level of side effects. With eight different atypicals now available, effective relapse prevention without relevant side effects can be achieved in most patients. Patients' perspective should be investigated in a systematic way, as it is of major importance for patients' long-term compliance and their willingness to take their medication regularly.

Key Words

schizophrenia - long term treatment - atypical antipsychotics- second-generation antipsychotics

Literatur

• 1 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
• 2 APA 2004
• 3 Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, Kelly C, King DJ. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment.  Schizophr Res. 2000;  45 47-56
• 4 Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis.  J Clin Psychiatry. 2005;  66 504-514
• 5 Casey DE. Tardive dyskinesia and atypical antipsychotic drugs.  Schizophr Res. 1999;  35 S61-S66
• 6 Correll. et al. .2004
• 7 Davis JM. Maintenance therapy and the natural course of schizophrenia.  J Clin Psychiatry. 1985;  46 18-21
• 8 Day JC, Bentall RP, Roberts C, Randall F. et al. . Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.  Arch Gen Psychiatry. 2005;  62 717-24
• 9 Eder U, Mangweth B, Ebenbichler C. et al. . Association of olanzapine-induced weight gain with an increase in body fat.  Am J Psychiatry. 2001;  158 1719-1722
• 10 Fleischhacker WW, Eerdekens M, Karcher K. et al. . Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.  J Clin Psychiatry. 2003;  64 1250-1257
• 11 Fleischhacker WW. Long acting intramuscular risperidone: a brief review. Hospital Pharmacy Europe in press
• 12 Gaebel W, Falkai P. Praxisleitlinien in Psychiatrie, Bd 1: Behandlungsleitlinien Schizophrenie. Darmstadt, Steinkopff 1998
• 13 Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review.  Acta Psychiatr Scand. 2002;  106 83-96
• 14 Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors.  Br J Psychiatry. 2005;  187 9-20
• 15 Henderson DC, Copeland PM, Daley TB. et al. . A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.  Am J Psychiatry. 2005;  162 954-962
• 16 Kane JM, Leucht S, Carpenter D. Expert Consensus Guidelines for Optimizing Pharmacologic Treatment of Psychotic Disorders.  J Clin Psychiatry. 2003;  64 5-19
• 17 Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia.  J Clin Psychiatry. 2001;  62 32-37
• 18 Katschnig H, Donat H, Fleischhacker WW. et al. .4x8 Empfehlungen zur Behandlung von Schizophrenie. Linz, Edition pro mente 2002
• 19 Lambert M, Conus P, Lambert T, McGorry P. Pharmacotherapy of first-episode schizophrenia.  Expert Opinion on Pharmacotherapy. 2003;  4 717-751
• 20 Lambert M, Naber D. Current issues in schizophrenia-overview of patient acceptability, functioning capacity and quality of life.  CNS Drugs. 2004;  18 5-17
• 21 Lambert M, Naber D. Current schizophrenia. Science Press Ltd 2004
• 22 Lambert M, Conus P, Lubman DI, Wade D, Yuen HP, Moritz S, Naber D, McGorry PD, Schimmelmann B. The impact of substance use disorders on clinical outcome in 668 patients with first-episode psychosis.  Acta Psychiatrica Scand. 2005;  112 141-148
• 23 Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition.  Am J Psychiatry. 2004;  161 1-56
• 24 Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.  Am J Psychiatry. 2003;  160 1209-22
• 25 Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry. 1996;  57 5-9
• 26 McGorry PD, Chanen A, McCarthy E, Van Riel R, McKenzie D, Singh BS. Posttraumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome.  J Nerv Ment Dis. 1991;  179 253-8
• 27 McGorry PD, Killackey E, Lambert T, Lambert M. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.  Aust N Z J Psychiatry. 2005;  39 1-30
• 28 Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics.  Drugs. 2004;  64 701-723
• 29 Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review.  Schizophr Res. 2004;  70 1-17
• 30 Moran P, Hodgins S. The correlates of comorbid antisocial personality disorder in schizophrenia.  Schizophr Bull. 2004;  30 791-802
• 31 Naber D. Subjective effects of antipsychotic treatment.  Acta Psychiatrica Scand. 2005;  111 81-83
• 32 National Institute for Clinical Excellence (NICE) .Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1. National Collaborating Centre for Mental Health 2002; www.nice.org.uk 2002
• 33 Nechmad A, Ratzoni G, Poyurovsky M, Meged S, Avidan G, Fuchs C, Bloch Y, Weizman R. Obsessive-compulsive disorder in adolescent schizophrenia patients.  Am J Psychiatry. 2003;  160 1002-4
• 34 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects.  CNS Drugs. 2005;  19 1-93
• 35 Pajonk. et al. .2005
• 36 Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G. HGDH Research Group.  Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.  Br J Psychiatry. 2004;  185 18-24
• 37 Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2004;  161 473-479
• 38 Schäfer und Lambert 2005
• 39 Sim K, Swapna V, Mythily S, Mahendran R, Kua EH, McGorry P, Chong SA. Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience.  Acta Psychiatr Scand. 2004;  109 23-9

Korrespondenzadresse